[
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About",
    "section": "",
    "text": "About this site"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Clinical Trial Watch",
    "section": "",
    "text": "This page monitors specific clinical trials and highlights any updates in their status or key fields.\nDownload Status Summary (CSV)\n\n\n\nTrial ID\nSponsor\nUpdate\nStatus\nConditions\nPhases\nStart\nEnd\nEnroll\nLast Updated\n\n\n\n\nNCT04818619\nAssiut University\nðŸŸ¢ No Change\nUNKNOWN\nChronic Myeloid Leukemia\nN/A\n2021-04\n2022-12\n65\nN/A\n\n\nNCT04150965\nMultiple Myeloma Research Consortium\nðŸŸ¢ No Change\nTERMINATED\nMultiple Myeloma, Relapsed Refractory Multiple Myeloma\nPHASE1, PHASE2\n2020-07-10\n2024-08-30\n14\nN/A\n\n\nNCT05607563\nBiotheus Inc.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumor\nPHASE1\n2022-11-21\n2023-12\n54\nN/A\n\n\nNCT05394168\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced/Metastatic Solid Tumors\nPHASE1\n2022-12-09\n2025-03-04\n12\nN/A\n\n\nNCT07171307\nInstituto de OftalmologÃ­a FundaciÃ³n Conde de Valenciana\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nConjunctivitis, Allergic\nN/A\n2026-01-01\n2026-09\n60\nN/A\n\n\nNCT04995523\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-Small-Cell Lung Carcinoma\nPHASE1, PHASE2\n2021-09-14\n2028-03-16\n210\nN/A\n\n\nNCT03119428\nOncoMed Pharmaceuticals, Inc.\nðŸŸ¢ No Change\nTERMINATED\nLocally Advanced Cancer, Metastatic Cancer\nPHASE1\n2017-05-02\n2019-05-15\n33\nN/A\n\n\nNCT04500678\nUniversity of Hawaii\nðŸŸ¢ No Change\nUNKNOWN\nHIV/AIDS\nPHASE2, PHASE3\n2019-02-01\n2022-12-31\n38\nN/A\n\n\nNCT05483400\nUniversity Medical Center Groningen\nðŸŸ¢ No Change\nRECRUITING\nHead and Neck Neoplasms, MSI-H Cancer, Melanoma\nPHASE2\n2023-10-18\n2027-09\n97\nN/A\n\n\nNCT05390528\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumors, Lymphoma, Metastatic Tumors\nPHASE1, PHASE2\n2022-06-20\n2024-12-30\n30\nN/A\n\n\nNCT06250036\nRoyal Marsden NHS Foundation Trust\nðŸŸ¢ No Change\nRECRUITING\nLocally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer\nPHASE2\n2025-02-20\n2031-09-01\n50\nN/A\n\n\nNCT05653284\nAkeso\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Malignant Tumors\nPHASE1\n2023-02-09\n2024-05-30\n19\nN/A\n\n\nNCT05102214\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nUNKNOWN\nLocally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer\nPHASE1, PHASE2\n2022-05-03\n2024-02\n150\nN/A\n\n\nNCT05023109\nShanghai Zhongshan Hospital\nðŸŸ¢ No Change\nUNKNOWN\nBiliary Tract Carcinoma\nPHASE2\n2021-02-01\n2024-12-01\n45\nN/A\n\n\nNCT05130177\nDiwakar Davar\nðŸŸ¢ No Change\nRECRUITING\nMelanoma\nPHASE2\n2022-03-16\n2031-01\n26\nN/A\n\n\nNCT04047862\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nLocally Advanced and Metastatic Solid Tumors\nPHASE1\n2019-08-15\n2024-08-07\n446\nN/A\n\n\nNCT05537051\nBiotheus Inc.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Solid Tumours\nPHASE1\n2023-10-30\n2025-12-31\n30\nN/A\n\n\nNCT05019677\nFudan University\nðŸŸ¢ No Change\nWITHDRAWN\nIntrahepatic Cholangiocarcinoma\nPHASE2\n2021-09-01\n2024-12-01\n0\nN/A\n\n\nNCT05061628\nShanghai Junshi Bioscience Co., Ltd.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumors\nPHASE1\n2021-04-21\n2024-09-30\n176\nN/A\n\n\nNCT04656535\nYale University\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nGlioblastoma\nEARLY_PHASE1\n2021-04-21\n2026-12-31\n46\nN/A\n\n\nNCT06773507\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\nðŸŸ¢ No Change\nRECRUITING\nAdvanced Esophageal Cancers, Advanced Non-small Cell Lung Cancer (NSCLC)\nPHASE1\n2025-05-12\n2027-06\n80\nN/A\n\n\nNCT06349980\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nRECRUITING\nCarcinoma, Hepatocellular\nPHASE2\n2024-08-05\n2027-02-10\n117\nN/A\n\n\nNCT05706207\nHuabo Biopharm Co., Ltd.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Solid Tumor\nPHASE1\n2021-12-21\n2023-09-30\n36\nN/A\n\n\nNCT05060432\niTeos Belgium SA\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma\nPHASE1, PHASE2\n2021-09-06\n2025-07\n153\nN/A\n\n\nNCT06713798\nGustave Roussy, Cancer Campus, Grand Paris\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nMetastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer\nPHASE2\n2025-07\n2030-01\n115\nN/A\n\n\nNCT05394337\nM.D.Â Anderson Cancer Center\nðŸŸ¢ No Change\nRECRUITING\nMetastatic Malignancy\nPHASE1, PHASE2\n2023-02-23\n2025-12-31\n10\nN/A\n\n\nNCT05253105\nShanghai Junshi Bioscience Co., Ltd.\nðŸŸ¢ No Change\nWITHDRAWN\nPreviously Treated, Advanced, Malignancies\nPHASE1\n2022-03-15\n2027-01\n0\nN/A\n\n\nNCT04270942\nProvention Bio, a Sanofi Company\nðŸŸ¢ No Change\nCOMPLETED\nDiabetes Mellitus, Type 1\nPHASE2\n2020-02-26\n2024-01-22\n6\nN/A\n\n\nNCT05294952\nAssiut University\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nPre-Eclampsia\nPHASE4\n2025-01-01\n2025-11-04\n82\nN/A\n\n\nNCT06754501\nM.D.Â Anderson Cancer Center\nðŸŸ¢ No Change\nRECRUITING\nCancer\nPHASE2\n2025-04-11\n2029-07-01\n35\nN/A\n\n\nNCT05757492\nCoherus Oncology, Inc.\nðŸŸ¢ No Change\nTERMINATED\nAdvanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma\nPHASE1\n2023-04-26\n2024-07-31\n22\nN/A\n\n\nNCT04952597\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nLimited Stage Small Cell Lung Cancer\nPHASE2\n2021-07-15\n2023-07-26\n126\nN/A\n\n\nNCT05805501\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nRenal Cell Carcinoma\nPHASE2\n2023-04-21\n2026-07-31\n199\nN/A\n\n\nNCT03447678\nFondazione IRCCS Istituto Nazionale dei Tumori, Milano\nðŸŸ¢ No Change\nUNKNOWN\nNon Small Cell Lung Cancer (NSCLC)\nPHASE2\n2018-05-23\n2022-05-31\n65\nN/A\n\n\nNCT04672369\nInnovent Biologics (Suzhou) Co.Â Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Lung Cancer\nPHASE1\n2021-06-06\n2023-06-01\n42\nN/A\n\n\nNCT04672356\nInnovent Biologics (Suzhou) Co.Â Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Lung Cancer\nPHASE1\n2021-01-25\n2023-06-01\n19\nN/A\n\n\nNCT05009069\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nRectal Neoplasms, Rectal Cancer\nPHASE2\n2022-03-18\n2026-11-06\n58\nN/A\n\n\nNCT04353830\nInnovent Biologics (Suzhou) Co.Â Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Malignancies\nPHASE1\n2020-05-22\n2022-05-11\n34\nN/A\n\n\nNCT07337447\nHospices Civils de Lyon\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nCarcinoma, Neuroendocrine\nPHASE2\n2026-04\n2030-04\n122\nN/A\n\n\nNCT04354246\nCompugen Ltd\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC\nPHASE1\n2020-03-31\n2025-12-30\n110\nN/A\n\n\nNCT04933227\nHoffmann-La Roche\nðŸŸ¢ No Change\nTERMINATED\nStomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma\nPHASE2\n2021-08-06\n2023-11-17\n29\nN/A\n\n\nNCT05414032\nUniversity Health Network, Toronto\nðŸŸ¢ No Change\nRECRUITING\nLocoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)\nPHASE2\n2023-07-12\n2026-07\n200\nN/A\n\n\nNCT06003621\nOmico\nðŸŸ¢ No Change\nRECRUITING\nSolid Tumor, Adult\nPHASE2\n2023-12-15\n2028-11-01\n96\nN/A\n\n\nNCT05568095\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Upper Gastrointestinal Tract Adenocarcinoma\nPHASE3\n2022-11-21\n2026-06\n1040\nN/A\n\n\nNCT06777628\nIRCCS Azienda Ospedaliero-Universitaria di Bologna\nðŸŸ¢ No Change\nRECRUITING\nLiver Cancer, Adult\nN/A\n2024-09-15\n2028-10-15\n100\nN/A\n\n\nNCT06773481\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\nðŸŸ¢ No Change\nRECRUITING\nGlioma, Glioma Tumor Recurrence, Glioma, Recurrent High Grade, Glioblastomas (GBM), Glioblastoma WHO Grade IV\nPHASE1\n2025-04-07\n2026-12\n40\nN/A\n\n\nNCT03708224\nAlain Algazi\nðŸŸ¢ No Change\nRECRUITING\nCancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer\nPHASE2\n2019-03-08\n2028-06-30\n55\nN/A\n\n\nNCT03652402\nAssistance Publique - HÃ´pitaux de Paris\nðŸŸ¢ No Change\nCOMPLETED\nKidney Transplant Rejection, Kidney Transplantation, Risk Stratification, Prognosis\nN/A\n2018-11-27\n2021-10-28\n558\nN/A\n\n\nNCT03486119\nYonsei University\nðŸŸ¢ No Change\nCOMPLETED\nNon -Small Cell Lung Cancer\nN/A\n2018-02-05\n2020-07-07\n60\nN/A\n\n\nNCT05120375\nBio-Thera Solutions\nðŸŸ¢ No Change\nTERMINATED\nSolid Tumor\nPHASE1\n2022-02-17\n2023-04-07\n5\nN/A\n\n\nNCT05327530\nEMD Serono Research & Development Institute, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nLocally Advanced or Metastatic Urothelial Carcinoma\nPHASE2\n2022-08-17\n2026-06-25\n256\nN/A\n\n\nNCT04570839\nCompugen Ltd\nðŸŸ¢ No Change\nCOMPLETED\nEndometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer\nPHASE1, PHASE2\n2020-08-31\n2024-05-15\n48\nN/A\n\n\nNCT05520294\nUniversity of Colorado, Denver\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nN/A\n2022-09-01\n2024-08-31\n90\nN/A\n\n\nNCT05417321\nShanghai Huaota Biopharmaceutical Co., Ltd.\nðŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumor, NSCLC\nPHASE1, PHASE2\n2022-08-25\n2025-08-01\n80\nN/A\n\n\nNCT06328036\nNational Cancer Institute (NCI)\nðŸŸ¢ No Change\nWITHDRAWN\nRecurrent Glioblastoma, IDH-Wildtype\nPHASE2\n2025-04-30\n2025-07-01\n0\nN/A\n\n\nNCT04465643\nSidney Kimmel Comprehensive Cancer Center at Johns Hopkins\nðŸŸ¢ No Change\nCOMPLETED\nNerve Sheath Tumors\nPHASE1\n2021-06-08\n2025-07-30\n13\nN/A\n\n\nNCT04262856\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer\nPHASE2\n2020-05-28\n2025-07-09\n151\nN/A\n\n\nNCT04736173\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer\nPHASE2\n2021-02-08\n2027-05\n169\nN/A\n\n\nNCT05126537\nSoutheast University, China\nðŸŸ¢ No Change\nUNKNOWN\n28 Day Mortality\nN/A\n2022-01-01\n2022-12-31\n100\nN/A\n\n\nNCT05289492\niTeos Therapeutics\nðŸŸ¢ No Change\nTERMINATED\nMultiple Myeloma\nPHASE1\n2022-05-01\n2023-11-29\n16\nN/A\n\n\nNCT07115043\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nMelanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma\nPHASE1, PHASE2\n2025-07-29\n2029-10-02\n60\nN/A\n\n\nNCT05743504\nNational Taiwan University Hospital\nðŸŸ¢ No Change\nUNKNOWN\nLocally Advanced Esophageal Squamous Cell Carcinoma\nPHASE1, PHASE2\n2023-09-18\n2025-11-30\n32\nN/A\n\n\nNCT05073484\nBio-Thera Solutions\nðŸŸ¢ No Change\nTERMINATED\nAdvanced Solid Tumor\nPHASE1\n2021-10-29\n2023-03-30\n13\nN/A\n\n\nNCT07376512\nCentre Georges Francois Leclerc\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nNon-Small Cell Lung Cancer, Melanoma (Skin Cancer)\nN/A\n2026-03-01\n2030-03-01\n378\nN/A\n\n\nNCT05904886\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nHepatocellular Carcinoma\nPHASE3\n2023-09-14\n2026-09-01\n687\nN/A\n\n\nNCT03739710\nGlaxoSmithKline\nðŸŸ¢ No Change\nCOMPLETED\nNeoplasms\nPHASE2\n2019-01-24\n2024-05-02\n175\nN/A\n\n\nNCT04791839\nWashington University School of Medicine\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer\nPHASE2\n2021-08-04\n2030-06-30\n30\nN/A\n\n\nNCT05020912\nCase Comprehensive Cancer Center\nðŸŸ¢ No Change\nRECRUITING\nBasal Cell Carcinoma\nPHASE2\n2021-12-13\n2027-12\n28\nN/A\n\n\nNCT06334406\nCentre Hospitalier Universitaire de Besancon\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nBladder Cancer\nN/A\n2024-04-02\n2026-04-02\n33\nN/A\n\n\nNCT07343310\nKine Sciences Co., Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nCIDP - Chronic Inflammatory Demyelinating Polyneuropathy\nPHASE1\n2024-08-27\n2025-04-14\n9\nN/A\n\n\nNCT03342417\nExcellaBio LLC\nðŸŸ¢ No Change\nTERMINATED\nBreast Cancer Female, Ovarian Cancer, Gastric Cancer\nPHASE2\n2018-02-14\n2019-05-29\n5\nN/A\n\n\nNCT04682665\nUniversity of Leeds\nðŸŸ¢ No Change\nCOMPLETED\nColon Cancer Liver Metastasis\nN/A\n2021-09-16\n2024-07-31\n81\nN/A\n\n\nNCT05123482\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nBreast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer\nPHASE1, PHASE2\n2021-10-18\n2027-09-29\n460\nN/A\n\n\nNCT07161414\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumors\nPHASE1\n2025-11-25\n2029-07-24\n40\nN/A\n\n\nNCT07015164\nAssistance Publique - HÃ´pitaux de Paris\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nHIV\nN/A\n2025-06-10\n2026-09-11\n80\nN/A\n\n\nNCT05702229\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nGastric Cancer\nPHASE2\n2023-01-16\n2027-09-28\n240\nN/A\n\n\nNCT07213882\nAssistance Publique - HÃ´pitaux de Paris\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nCutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome\nEARLY_PHASE1\n2026-01-01\n2028-08-01\n30\nN/A\n\n\nNCT03628677\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nSolid Tumor, Unspecified, Adult\nPHASE1\n2018-09-12\n2025-01-23\n75\nN/A\n\n\nNCT06897436\nMedical University of Lublin\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nEndometriosis\nN/A\n2025-05-01\n2029-12-31\n60\nN/A\n\n\nNCT05633927\nHospitales Universitarios Virgen del RocÃ­o\nðŸŸ¢ No Change\nCOMPLETED\nSARS-CoV-2 RNA Vaccines, HIV Infection\nN/A\n2021-04-01\n2022-12-01\n48\nN/A\n\n\nNCT04836507\nCurocell Inc.\nðŸŸ¢ No Change\nRECRUITING\nRelapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal Large B-Cell Lymphoma (PMBCL), High-grade B-cell Lymphoma, Transformed Follicular Lymphoma (TFL)\nPHASE1, PHASE2\n2021-03-02\n2028-02\n91\nN/A\n\n\nNCT05775159\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nHepatocellular Carcinoma, Biliary Tract Cancer\nPHASE2\n2023-04-24\n2027-10-28\n294\nN/A\n\n\nNCT06338657\nUniversity of Southern California\nðŸŸ¢ No Change\nTERMINATED\nHead and Neck Squamous Cell Carcinoma\nPHASE1\n2024-04-01\n2025-09-09\n1\nN/A\n\n\nNCT06860815\nCity of Hope Medical Center\nðŸŸ¢ No Change\nRECRUITING\nAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver\nPHASE2\n2026-04-01\n2027-01-30\n11\nN/A\n\n\nNCT04624828\nIstituto Clinico Humanitas\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nOligorecurrent and Oligoprogressive Prostate Cancer Patients\nNA\n2020-10-19\n2026-07\n40\nN/A\n\n\nNCT05574335\nNational Institute of Allergy and Infectious Diseases (NIAID)\nðŸŸ¢ No Change\nTERMINATED\nType 1 Diabetes Mellitus\nPHASE1, PHASE2\n2023-04-26\n2025-10-20\n8\nN/A\n\n\nNCT06302556\nFondazione IRCCS Caâ€™ Granda, Ospedale Maggiore Policlinico\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nLung Transplant Rejection\nN/A\n2024-04\n2026-02\n280\nN/A\n\n\nNCT04761198\nMereo BioPharma\nðŸŸ¢ No Change\nCOMPLETED\nSolid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor\nPHASE1, PHASE2\n2021-03-23\n2023-10-30\n76\nN/A\n\n\nNCT04693234\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nCervical Cancer\nPHASE2\n2021-02-15\n2023-08-31\n178\nN/A\n\n\nNCT03563716\nGenentech, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nNon-small Cell Lung Cancer\nPHASE2\n2018-08-10\n2025-11-24\n135\nN/A\n\n\nNCT07324642\nKine Sciences Co., Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nHealthy Volunteers\nPHASE1\n2025-05-26\n2025-08-25\n24\nN/A\n\n\nNCT05809895\nNovartis Pharmaceuticals\nðŸŸ¢ No Change\nWITHDRAWN\nTriple Negative Breast Cancer\nPHASE2\n2023-09-15\n2029-07-18\n0\nN/A\n\n\nNCT04732494\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nEsophageal Squamous Cell Carcinoma\nPHASE2\n2021-03-31\n2023-12-26\n125\nN/A\n\n\nNCT05645692\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nUrothelial Cancer\nPHASE2\n2023-04-13\n2026-12-31\n204\nN/A\n\n\nNCT04457778\nEMD Serono Research & Development Institute, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nMetastatic Solid Tumors\nPHASE1\n2020-07-10\n2023-06-23\n58\nN/A\n\n\nNCT03772899\nLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St.Â Josephâ€™s\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nPHASE1\n2019-03-27\n2026-08\n20\nN/A\n\n\nNCT04374877\nCoherus Oncology, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer\nPHASE1\n2020-04-22\n2025-06-05\n145\nN/A\n\n\nNCT06346197\nCentre Leon Berard\nðŸŸ¢ No Change\nRECRUITING\nGastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer\nPHASE3\n2025-12-08\n2028-05-15\n132\nN/A\n\n\nNCT05780073\nFundaciÃ³ Institut Germans Trias i Pujol\nðŸŸ¢ No Change\nCOMPLETED\nHIV Infection Primary\nPHASE2\n2023-10-16\n2025-04-01\n60\nN/A\n\n\nNCT03667716\nCompugen Ltd\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer\nPHASE1\n2018-09-06\n2024-01-30\n121\nN/A\n\n\nNCT06784947\nUniversity of Colorado, Denver\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMicrosatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV\nPHASE2\n2025-03-25\n2028-05\n13\nN/A\n\n\nNCT05014815\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nLocally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV\nPHASE2\n2021-11-16\n2024-09-04\n272\nN/A\n\n\nNCT07307053\nCancer Institute and Hospital, Chinese Academy of Medical Sciences\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nRare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors\nPHASE1, PHASE2\n2026-01-01\n2031-01-31\n600\nN/A\n\n\nNCT04746924\nBeiGene\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon-small Cell Lung Cancer, NSCLC\nPHASE3\n2021-06-08\n2026-03-31\n662\nN/A\n\n\nNCT07098338\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-Small Cell Lung Cancer\nPHASE2\n2025-08-07\n2029-04-06\n278\nN/A\n\n\nNCT06532539\nShandong Cancer Hospital and Institute\nðŸŸ¢ No Change\nRECRUITING\nEndometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis\nPHASE2\n2024-06-13\n2026-05\n30\nN/A\n\n\nNCT06864598\nPeking University Peopleâ€™s Hospital\nðŸŸ¢ No Change\nENROLLING_BY_INVITATION\nGraft-versus-host Disease (GVHD)\nN/A\n2025-01-09\n2026-10-31\n100\nN/A\n\n\nNCT03661047\nMassachusetts General Hospital\nðŸŸ¢ No Change\nWITHDRAWN\nColon Cancer\nPHASE2\n2019-11-30\n2021-11-30\n0\nN/A\n\n\nNCT04866017\nBeiGene\nðŸŸ¢ No Change\nTERMINATED\nNon Small Cell Lung Cancer\nPHASE3\n2021-06-17\n2023-10-17\n63\nN/A\n\n\nNCT05127824\nJodi Maranchie\nðŸŸ¢ No Change\nRECRUITING\nCarcinoma, Renal Cell\nPHASE2\n2023-07-06\n2026-12\n42\nN/A\n\n\nNCT04303169\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE1, PHASE2\n2020-06-26\n2025-09-24\n146\nN/A\n\n\nNCT05329766\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nGastrointestinal Tract Malignancies\nPHASE2\n2022-06-10\n2027-06\n332\nN/A\n\n\nNCT04323202\nCase Comprehensive Cancer Center\nðŸŸ¢ No Change\nCOMPLETED\nBasal Cell Carcinoma of the Head and Neck\nPHASE1\n2020-08-04\n2025-06-25\n13\nN/A\n\n\nNCT07221253\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nBiliary Tract Cancer\nPHASE3\n2025-12-04\n2029-07-04\n1100\nN/A\n\n\nNCT05676931\nGilead Sciences\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Non-Small Cell Lung Cancer\nPHASE2\n2023-02-21\n2027-12\n400\nN/A\n\n\nNCT06790706\nHospices Civils de Lyon\nðŸŸ¢ No Change\nRECRUITING\nPeritoneal Mesothelioma, Gestational Trophoblastic Tumor, Thymoma and Thymic Carcinoma, Anaplastic Thyroid Carcinomas, Gastroenteropancreatic Neuroendocrine Tumor, Carcinoid Tumor\nPHASE2\n2025-10-01\n2031-06\n154\nN/A\n\n\nNCT04543617\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nEsophageal Squamous Cell Carcinoma\nPHASE3\n2020-09-28\n2027-03-31\n760\nN/A\n\n\nNCT04305041\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE1, PHASE2\n2020-06-26\n2025-08-25\n100\nN/A\n\n\nNCT06996782\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nAdvanced or Metastatic Non-small Cell Lung Cancer\nPHASE1, PHASE2\n2025-11-24\n2029-02-23\n152\nN/A\n\n\nNCT05665595\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE3\n2023-01-19\n2025-09-26\n1594\nN/A\n\n\nNCT06868277\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nCarcinoma, Non-Small Cell Lung\nPHASE3\n2025-04-10\n2030-12-02\n830\nN/A\n\n\nNCT06692738\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-small Cell Lung Cancer\nPHASE3\n2024-11-18\n2029-10-08\n880\nN/A\n\n\nNCT04774484\nFrancesc Marti\nðŸŸ¢ No Change\nWITHDRAWN\nEnd Stage Renal Disease\nNA\n2023-01\n2026-06-30\n0\nN/A\n\n\nNCT04256421\nHoffmann-La Roche\nðŸŸ¢ No Change\nCOMPLETED\nSmall Cell Lung Cancer\nPHASE3\n2020-02-04\n2025-07-31\n490\nN/A\n\n\nNCT06989112\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nEndometrial Cancer\nPHASE3\n2025-03-27\n2031-02-19\n600\nN/A\n\n\nNCT05816460\nUniversity College Dublin\nðŸŸ¢ No Change\nUNKNOWN\nInsomnia, Cancer\nNA\n2023-05-22\n2024-06-10\n308\nN/A\n\n\nNCT06627647\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-squamous Non-small Cell Lung Cancer\nPHASE3\n2024-11-27\n2030-03-25\n878\nN/A\n\n\nNCT04305054\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nPHASE1, PHASE2\n2020-07-01\n2026-04-20\n315\nN/A\n\n\nNCT04294810\nHoffmann-La Roche\nðŸŸ¢ No Change\nCOMPLETED\nNon-Small Cell Lung Cancer\nPHASE3\n2020-03-04\n2025-12-30\n620\nN/A\n\n\nNCT03198546\nSecond Affiliated Hospital of Guangzhou Medical University\nðŸŸ¢ No Change\nRECRUITING\nHepatocellular Carcinoma, Immunotherapy, CAR, GPC3 Gene Inactivation, T Cell, Squamous Cell Lung Cancer\nPHASE1\n2017-07-01\n2036-08-01\n30\nN/A\n\n\nNCT03198052\nSecond Affiliated Hospital of Guangzhou Medical University\nðŸŸ¢ No Change\nRECRUITING\nLung Cancer, Cancer, Immunotherapy, CAR-T Cell\nPHASE1\n2017-07-01\n2036-08-01\n30\nN/A\n\n\nNCT04585815\nPfizer\nðŸŸ¢ No Change\nTERMINATED\nCarcinoma, Non-Small-Cell Lung\nPHASE1, PHASE2\n2020-11-10\n2024-10-29\n34\nN/A\n\n\nNCT02443155\nNovo Nordisk A/S\nðŸŸ¢ No Change\nCOMPLETED\nDiabetes, Diabetes Mellitus, Type 1\nPHASE2\n2015-11-10\n2019-02-27\n308\nN/A\n\n\n\nView Full Change History"
  },
  {
    "objectID": "history.html",
    "href": "history.html",
    "title": "Change History",
    "section": "",
    "text": "Below is the history of detected changes for the monitored trials.\nNo history recorded yet.\nBack to Status Summary"
  },
  {
    "objectID": "history.html#historical-updates",
    "href": "history.html#historical-updates",
    "title": "Change History",
    "section": "",
    "text": "Below is the history of detected changes for the monitored trials.\nNo history recorded yet.\nBack to Status Summary"
  },
  {
    "objectID": "full_data.html",
    "href": "full_data.html",
    "title": "Full Snapshot Data",
    "section": "",
    "text": "This page displays the consolidated raw data from all monitored trial snapshots. This includes all fields from ClinicalTrials.gov in a flattened format.\nDownload Full Snapshots (CSV)\n\n\n\nBack to Status Summary"
  },
  {
    "objectID": "full_data.html#comprehensive-dataset",
    "href": "full_data.html#comprehensive-dataset",
    "title": "Full Trial Data",
    "section": "",
    "text": "This page displays the complete dataset of monitored clinical trials, imported from the latest summary report.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nid\nname\nsponsor\nlast_update_posted\nstudy_start\nenrollment\nprimary_outcome\nstatus\nlast_changed\ndetails\n\n\n\n\nNCT04818619\nTIGIT in Patients With Chronic Myeloid Leukemia\nAssiut University\n2021-03-29\n2021-04\n65\nTIGIT expression frequency on NK cells\nNo Change\nNo changes yet\n\n\n\nNCT04150965\nImmuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT\nMultiple Myeloma Research Consortium\n2025-02-14\n2020-07-10\n14\nOverall Response Rate\nNo Change\nNo changes yet\n\n\n\nNCT05607563\nA Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours\nBiotheus Inc.\n2023-02-08\n2022-11-21\n54\nDose Limited Toxicityï¼ˆDLTï¼‰\nNo Change\nNo changes yet\n\n\n\nNCT05394168\nA Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors\nShanghai Henlius Biotech\n2024-04-01\n2022-12-09\n12\nAdverse event\nNo Change\nNo changes yet\n\n\n\nNCT07171307\nTreg Effector Function and Th2/Treg Ratio in Allergic Conjunctivitis: Effect of Desensitization Therapy\nInstituto de OftalmologÃ­a FundaciÃ³n Conde de Valenciana\n2025-09-17\n2026-01-01\n60\nTo evaluate the effector function and the expression of TIGIT and PD-1 molecules on regulatory T cells, as well as the Th2/Treg, in patients with allergic conjunctivitis with and without allergen-specific immunotherapy, and in healthy control subjects.\nNo Change\nNo changes yet\n\n\n\nNCT04995523\nA Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC\nAstraZeneca\n2025-11-24\n2021-09-14\n210\nPercentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters\nNo Change\nNo changes yet\n\n\n\nNCT03119428\nA Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors\nOncoMed Pharmaceuticals, Inc.\n2020-08-11\n2017-05-02\n33\nIncidence of dose limiting toxicities (DLTs)\nNo Change\nNo changes yet\n\n\n\nNCT04500678\nImpact of Metformin on Immuno-virologic Parameters in HIV\nUniversity of Hawaii\n2020-08-05\n2019-02-01\n38\nCD4 T cell PD1+TIGIT+\nNo Change\nNo changes yet\n\n\n\nNCT05483400\nOpen Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors\nUniversity Medical Center Groningen\n2025-03-30\n2023-10-18\n97\nPathologic response in cohort 1\nNo Change\nNo changes yet\n\n\n\nNCT05390528\nA Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGITÃ—PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma\nShanghai Henlius Biotech\n2023-08-08\n2022-06-20\n30\nPhase 1a: The incidence, nature, and severity of adverse events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 in patients receiving the trial drug\nNo Change\nNo changes yet\n\n\n\nNCT06250036\nZimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer\nRoyal Marsden NHS Foundation Trust\n2025-08-21\n2025-02-20\n50\nEfficacy of zimberelimab +/- domvanalimab in patients with resectable MMRd/MSI-H gastric/GOJ adenocarcinoma who proceed to surgery\nNo Change\nNo changes yet\n\n\n\nNCT05653284\nA Study of AK130 in Patients With Advanced Malignant Tumors\nAkeso\n2024-08-13\n2023-02-09\n19\nIncidence and severity of participants with adverse events (AEs)\nNo Change\nNo changes yet\n\n\n\nNCT05102214\nHLX301 (TIGITÃ—PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors\nShanghai Henlius Biotech\n2023-08-08\n2022-05-03\n150\nPhase 1a: Safety assessments in patients receiving the trial drug\nNo Change\nNo changes yet\n\n\n\nNCT05023109\nGP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC\nShanghai Zhongshan Hospital\n2023-08-15\n2021-02-01\n45\nObjective response rate (ORR)\nNo Change\nNo changes yet\n\n\n\nNCT05130177\nZimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma\nDiwakar Davar\n2025-05-07\n2022-03-16\n26\nObjective Response Rate (ORR)\nNo Change\nNo changes yet\n\n\n\nNCT04047862\nStudy of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors\nBeiGene\n2025-08-22\n2019-08-15\n446\nPhase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)\nNo Change\nNo changes yet\n\n\n\nNCT05537051\nA Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-Î²) in Patients With Advanced Solid Tumours\nBiotheus Inc.\n2023-02-08\n2023-10-30\n30\nDLT\nNo Change\nNo changes yet\n\n\n\nNCT05019677\nGP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC\nFudan University\n2022-04-04\n2021-09-01\n0\nObjective response rate (ORR)\nNo Change\nNo changes yet\n\n\n\nNCT05061628\nThe Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor\nShanghai Junshi Bioscience Co., Ltd.\n2021-09-29\n2021-04-21\n176\nTo evaluate the safety and tolerability of JS006 as Monotherapy and in combination with toripalimab in patients with advanced tumors\nNo Change\nNo changes yet\n\n\n\nNCT04656535\nAB154 Combined With AB122 for Recurrent Glioblastoma\nYale University\n2026-01-07\n2021-04-21\n46\nIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability] associated with the combination AB122 and AB154 in patients with recurrent glioblastoma\nNo Change\nNo changes yet\n\n\n\nNCT06773507\nPhase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\n2025-07-09\n2025-05-12\n80\nObjective response rate (ORR)\nNo Change\nNo changes yet\n\n\n\nNCT06349980\nA Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.\nShanghai Henlius Biotech\n2024-12-18\n2024-08-05\n117\nORR\nNo Change\nNo changes yet\n\n\n\nNCT05706207\nA Study of HB0030 Injection in Patients With Advanced Solid Tumors\nHuabo Biopharm Co., Ltd.\n2023-01-31\n2021-12-21\n36\nDose Limiting Toxicity(DLT)\nNo Change\nNo changes yet\n\n\n\nNCT05060432\nStudy of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors\niTeos Belgium SA\n2024-06-21\n2021-09-06\n153\nPercentage of participants with DLT and Adverse Events\nNo Change\nNo changes yet\n\n\n\nNCT06713798\nTargeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures\nGustave Roussy, Cancer Campus, Grand Paris\n2025-06-24\n2025-07\n115\nBest overall response (BOR) rate\nNo Change\nNo changes yet\n\n\n\nNCT05394337\nNeoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma\nM.D.Â Anderson Cancer Center\n2025-10-09\n2023-02-23\n10\nTo evaluate relapse-free survival (RFS)\nNo Change\nNo changes yet\n\n\n\nNCT05253105\nA Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies\nShanghai Junshi Bioscience Co., Ltd.\n2022-05-31\n2022-03-15\n0\nTo assess the safety and tolerability of multiple doses of TAB006 in combination with toripalimab.\nNo Change\nNo changes yet\n\n\n\nNCT04270942\nAt-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)\nProvention Bio, a Sanofi Company\n2025-02-12\n2020-02-26\n6\nNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Adverse Events of Special Interest (TEAESIs) and Treatment-emergent Serious Adverse Events (TESAEs)\nNo Change\nNo changes yet\n\n\n\nNCT05294952\nco Ihibtory Receptor in Preeclampsia\nAssiut University\n2024-02-05\n2025-01-01\n82\nearly detection of preeclampsia\nNo Change\nNo changes yet\n\n\n\nNCT06754501\nA Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary\nM.D.Â Anderson Cancer Center\n2025-10-07\n2025-04-11\n35\nSafety and Adverse Events (AEs)\nNo Change\nNo changes yet\n\n\n\nNCT05757492\nStudy to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors\nCoherus Oncology, Inc.\n2025-05-01\n2023-04-26\n22\nAssessment of the number of participants with treatment-emergent adverse events (TEAEs) receiving CHS-006 administered in combination with toripalimab\nNo Change\nNo changes yet\n\n\n\nNCT04952597\nStudy of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer\nBeiGene\n2024-10-26\n2021-07-15\n126\nProgression Free Survival (PFS)\nNo Change\nNo changes yet\n\n\n\nNCT05805501\nA Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma\nHoffmann-La Roche\n2025-11-13\n2023-04-21\n199\nIncidence and Severity of Adverse Events (AEs)\nNo Change\nNo changes yet\n\n\n\nNCT03447678\nPembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.\nFondazione IRCCS Istituto Nazionale dei Tumori, Milano\n2021-06-09\n2018-05-23\n65\nImmune biomarkers\nNo Change\nNo changes yet\n\n\n\nNCT04672369\nA Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC\nInnovent Biologics (Suzhou) Co.Â Ltd.\n2023-06-22\n2021-06-06\n42\nObjective response rate(ORR)\nNo Change\nNo changes yet\n\n\n\nNCT04672356\nA Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer\nInnovent Biologics (Suzhou) Co.Â Ltd.\n2023-06-22\n2021-01-25\n19\nAdverse Events\nNo Change\nNo changes yet\n\n\n\nNCT05009069\nA Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer\nHoffmann-La Roche\n2026-01-22\n2022-03-18\n58\nPercentage of Participants With Pathological Complete Response (pCR)\nNo Change\nNo changes yet\n\n\n\nNCT04353830\nA Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors\nInnovent Biologics (Suzhou) Co.Â Ltd.\n2023-03-01\n2020-05-22\n34\nNumber of subjects with AEs and SAEs\nNo Change\nNo changes yet\n\n\n\nNCT07337447\nTrial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)\nHospices Civils de Lyon\n2026-01-13\n2026-04\n122\nOverall survival (%) between FOLFIRI and FOLFIRI+Zimberelimab+Domvanalimab\nNo Change\nNo changes yet\n\n\n\nNCT04354246\nCOM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies\nCompugen Ltd\n2025-05-22\n2020-03-31\n110\nThe safety and tolerability of COM902 monotherapy and in combination with COM701.\nNo Change\nNo changes yet\n\n\n\nNCT04933227\nA Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)\nHoffmann-La Roche\n2024-11-14\n2021-08-06\n29\nObjective Response Rate (ORR) in the Full Analysis Set (FAS) Population\nNo Change\nNo changes yet\n\n\n\nNCT05414032\nMolecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC\nUniversity Health Network, Toronto\n2025-03-30\n2023-07-12\n200\nEfficacy (in terms of ctDNA clearance) of AZD2936 compared to observation (Standard of Care, SOC) in LA-HNSCC patients who have MRD (MRD+) after definitive treatment.\nNo Change\nNo changes yet\n\n\n\nNCT06003621\nTiragolumab and Atezolizumab in Advanced Pan-cancer Patients\nOmico\n2024-11-15\n2023-12-15\n96\nProgression Free Survival (PFS) rate at 6 Months\nNo Change\nNo changes yet\n\n\n\nNCT05568095\nA Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body\nArcus Biosciences, Inc.\n2026-02-02\n2022-11-21\n1040\nOverall survival\nNo Change\nNo changes yet\n\n\n\nNCT06777628\nImmunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma\nIRCCS Azienda Ospedaliero-Universitaria di Bologna\n2025-01-16\n2024-09-15\n100\nTo find predictive biomarkers of response to immunotherapy in HCC\nNo Change\nNo changes yet\n\n\n\nNCT06773481\nBC008-1A Injection for Recurrent CNS WHO G4 Glioma\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\n2025-07-09\n2025-04-07\n40\nSafety\nNo Change\nNo changes yet\n\n\n\nNCT03708224\nPreoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck\nAlain Algazi\n2025-01-28\n2019-03-08\n55\nProportion of subjects with a &gt;= 40% increase in the cluster of differentiation 3 (CD3) counts\nNo Change\nNo changes yet\n\n\n\nNCT03652402\nPrecision Risk Stratification in Kidney Transplant Patients - EU-TRAIN\nAssistance Publique - HÃ´pitaux de Paris\n2024-06-05\n2018-11-27\n558\nCapacity of non-invasive biomarkers and intragraft gene expression profiles combined to standard of care data (HLA system, clinical and biological data)\nNo Change\nNo changes yet\n\n\n\nNCT03486119\nA Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients\nYonsei University\n2020-10-19\n2018-02-05\n60\nMDSC markers\nNo Change\nNo changes yet\n\n\n\nNCT05120375\nAssessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in China\nBio-Thera Solutions\n2023-10-11\n2022-02-17\n5\nDose-limiting toxicity(DLT)\nNo Change\nNo changes yet\n\n\n\nNCT05327530\nA Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)\nEMD Serono Research & Development Institute, Inc.\n2026-01-26\n2022-08-17\n256\nProgression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator\nNo Change\nNo changes yet\n\n\n\nNCT04570839\nCOM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.\nCompugen Ltd\n2024-07-18\n2020-08-31\n48\nThe proportion of subjects with adverse events on the study.\nNo Change\nNo changes yet\n\n\n\nNCT05520294\nEvaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant Melanoma\nUniversity of Colorado, Denver\n2024-04-17\n2022-09-01\n90\nGrade of TIL in melanoma biopsy\nNo Change\nNo changes yet\n\n\n\nNCT05417321\nA Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors\nShanghai Huaota Biopharmaceutical Co., Ltd.\n2025-01-03\n2022-08-25\n80\nSafety and tolerability\nNo Change\nNo changes yet\n\n\n\nNCT06328036\nTesting the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma\nNational Cancer Institute (NCI)\n2024-12-30\n2025-04-30\n0\nProgression free survival (PFS)\nNo Change\nNo changes yet\n\n\n\nNCT04465643\nNeoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor\nSidney Kimmel Comprehensive Cancer Center at Johns Hopkins\n2025-10-08\n2021-06-08\n13\nSafety of combination nivolumab and ipilimumab as assessed by number of participants who experience adverse events\nNo Change\nNo changes yet\n\n\n\nNCT04262856\nStudy to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer\nArcus Biosciences, Inc.\n2025-08-26\n2020-05-28\n151\nObjective response rate (ORR)\nNo Change\nNo changes yet\n\n\n\nNCT04736173\nStudy Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer\nArcus Biosciences, Inc.\n2025-12-15\n2021-02-08\n169\nProgression-free Survival (PFS)\nNo Change\nNo changes yet\n\n\n\nNCT05126537\nCo-inhibitory Molecules on Treg and miR-155-5p in Patients With Sepsis\nSoutheast University, China\n2022-11-30\n2022-01-01\n100\n28 day mortality\nNo Change\nNo changes yet\n\n\n\nNCT05289492\nStudy of Novel Regimens in Relapsed or Refractory Multiple Myeloma\niTeos Therapeutics\n2024-10-26\n2022-05-01\n16\nNumber of participants with any adverse events (AEs) and serious adverse events (SAEs)\nNo Change\nNo changes yet\n\n\n\nNCT07115043\nA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors\nAstraZeneca\n2025-12-19\n2025-07-29\n60\nSafety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion)\nNo Change\nNo changes yet\n\n\n\nNCT05743504\nImmunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients\nNational Taiwan University Hospital\n2024-02-02\n2023-09-18\n32\nPathological complete response rate\nNo Change\nNo changes yet\n\n\n\nNCT05073484\nAssessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients\nBio-Thera Solutions\n2023-10-11\n2021-10-29\n13\nDose-limiting toxicity(DLT)\nNo Change\nNo changes yet\n\n\n\nNCT07376512\nPredicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis\nCentre Georges Francois Leclerc\n2026-01-29\n2026-03-01\n378\nTarget protein levels in plasma-derived extracellular vesicles (EVs) measured by multiplex ELISA before treatment\nNo Change\nNo changes yet\n\n\n\nNCT05904886\nA Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)\nHoffmann-La Roche\n2025-12-31\n2023-09-14\n687\nInvestigator-assessed Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\nNo Change\nNo changes yet\n\n\n\nNCT03739710\nPlatform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)\nGlaxoSmithKline\n2025-06-15\n2019-01-24\n175\nNumber of Participants Randomized Across Sub-studies\nNo Change\nNo changes yet\n\n\n\nNCT04791839\nSafety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer\nWashington University School of Medicine\n2025-11-05\n2021-08-04\n30\nObjective response rate (ORR)\nNo Change\nNo changes yet\n\n\n\nNCT05020912\nAlteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy\nCase Comprehensive Cancer Center\n2025-11-26\n2021-12-13\n28\nTime to maximum expression of immune checkpoint molecules\nNo Change\nNo changes yet\n\n\n\nNCT06334406\nAntitumor T Cell Responses in Patients With Bladder Cancer\nCentre Hospitalier Universitaire de Besancon\n2024-03-28\n2024-04-02\n33\nTumor antigen specific T-cell responses\nNo Change\nNo changes yet\n\n\n\nNCT07343310\nA First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory CIDP\nKine Sciences Co., Ltd.\n2026-01-20\n2024-08-27\n9\nIncidence of Adverse Events (AEs)\nNo Change\nNo changes yet\n\n\n\nNCT03342417\nCombination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients\nExcellaBio LLC\n2021-11-09\n2018-02-14\n5\nNumber of participants with treatment-related adverse events as assessed by CTCAE v4.0\nNo Change\nNo changes yet\n\n\n\nNCT04682665\nPrebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases\nUniversity of Leeds\n2024-12-04\n2021-09-16\n81\nAbundance of individual bacterial taxa in the gut microbiome (eg. Bifidobacterium, Lactobacillus, and Fusobacterium) in stool samples.\nNo Change\nNo changes yet\n\n\n\nNCT05123482\nA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies\nAstraZeneca\n2025-12-08\n2021-10-18\n460\nThe number of patients with adverse events\nNo Change\nNo changes yet\n\n\n\nNCT07161414\nA Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy\nAstraZeneca\n2025-12-24\n2025-11-25\n40\nArea under the Concentration-time Curve During One Dosing Interval (AUCtau)\nNo Change\nNo changes yet\n\n\n\nNCT07015164\nRole of Viral Reservoir, Immune Activation and Depletion in Persistent Viremia Persistent Viremia in People Living With HIV on Antiretroviral Therapy\nAssistance Publique - HÃ´pitaux de Paris\n2025-06-11\n2025-06-10\n80\nQuantification of HIV-1 cellular reservoir parameters using molecular techniques\nNo Change\nNo changes yet\n\n\n\nNCT05702229\nNovel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma\nAstraZeneca\n2025-11-17\n2023-01-16\n240\nORR (per RECIST 1.1 as assessed by Investigator)\nNo Change\nNo changes yet\n\n\n\nNCT07213882\nA Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeuticsâ€™â€™ Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)\nAssistance Publique - HÃ´pitaux de Paris\n2025-10-09\n2026-01-01\n30\nDose limiting toxicity (DLT) defined by any treatment-emergent adverse event (TEAE) not attributable to the disease or disease-related processes\nNo Change\nNo changes yet\n\n\n\nNCT03628677\nA Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies\nArcus Biosciences, Inc.\n2025-02-04\n2018-09-12\n75\nNumber of Participants with Treatment Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0\nNo Change\nNo changes yet\n\n\n\nNCT06897436\nCharacterization of Immune Cells and Their Secreted Cytokines in Endometriosis Patients\nMedical University of Lublin\n2025-03-27\n2025-05-01\n60\nAlterations in immune system cell phenotype and activity associated with endometriosis.\nNo Change\nNo changes yet\n\n\n\nNCT05633927\nHumoral and Cellular Immunity Against SARS-COV-2 Vaccine in HIV-infected Patients Immunosuppressed\nHospitales Universitarios Virgen del RocÃ­o\n2024-10-15\n2021-04-01\n48\nAntibodies\nNo Change\nNo changes yet\n\n\n\nNCT04836507\nStudy of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients\nCurocell Inc.\n2021-05-03\n2021-03-02\n91\nPhase 1 Study: Maximum Tolerated Dose (MTD) which will be the Recommended Phase 2 Dose (RP2D)\nNo Change\nNo changes yet\n\n\n\nNCT05775159\nStudy of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer\nAstraZeneca\n2025-11-13\n2023-04-24\n294\nObjective response rate (ORR)\nNo Change\nNo changes yet\n\n\n\nNCT06338657\nFID-007 Followed by Standard of Care Surgery in Head and Neck Cancer\nUniversity of Southern California\n2025-09-16\n2024-04-01\n1\nEvaluate the phenotypical and functional changes of different T cell subsets within the tumor microenvironment after treatment with FID-007\nNo Change\nNo changes yet\n\n\n\nNCT06860815\nCemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer\nCity of Hope Medical Center\n2026-01-28\n2026-04-01\n11\nCD8+ T cell infiltration in tumor microenvironment (TME): baseline\nNo Change\nNo changes yet\n\n\n\nNCT04624828\nImmune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT\nIstituto Clinico Humanitas\n2025-04-24\n2020-10-19\n40\nimmune evaluation\nNo Change\nNo changes yet\n\n\n\nNCT05574335\nSiplizumab in T1DM\nNational Institute of Allergy and Infectious Diseases (NIAID)\n2026-01-06\n2023-04-26\n8\nNumber of Participants with a T cell phenotype signature response\nNo Change\nNo changes yet\n\n\n\nNCT06302556\nThe Role of Immune Checkpoints in Lung Transplant (ILTRA)\nFondazione IRCCS Caâ€™ Granda, Ospedale Maggiore Policlinico\n2024-03-08\n2024-04\n280\nLung-tissue immune-checkpoint profile and bronchoalveolar immune-cells mRNA signature in acute rejection after lung transplantation.\nNo Change\nNo changes yet\n\n\n\nNCT04761198\nA Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors\nMereo BioPharma\n2025-03-17\n2021-03-23\n76\nObjective Response Rate (ORR) as Assessed Based on Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)\nNo Change\nNo changes yet\n\n\n\nNCT04693234\nAdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer\nBeiGene\n2025-04-27\n2021-02-15\n178\nCohort 1: Objective Response Rate (ORR) Assessed by an Independent Review Committee (IRC) in PD-L1-Positive Participants\nNo Change\nNo changes yet\n\n\n\nNCT03563716\nA Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-NaÃ¯ve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer\nGenentech, Inc.\n2026-01-20\n2018-08-10\n135\nObjective Response Rate (ORR)\nNo Change\nNo changes yet\n\n\n\nNCT07324642\nA Phase 1 MAD Study of KINE-101 in Healthy Volunteers\nKine Sciences Co., Ltd.\n2026-01-07\n2025-05-26\n24\nIncidence of Treatment-Emergent Adverse Events\nNo Change\nNo changes yet\n\n\n\nNCT05809895\nPhase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer\nNovartis Pharmaceuticals\n2023-07-24\n2023-09-15\n0\nProgression-free Survival (PFS) based on investigator assessment using RECIST 1.1 criteria in Arm A and B\nNo Change\nNo changes yet\n\n\n\nNCT04732494\nAnti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma\nBeiGene\n2025-01-31\n2021-03-31\n125\nObjective Response Rate (ORR) Assessed by the Investigator\nNo Change\nNo changes yet\n\n\n\nNCT05645692\nA Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer\nHoffmann-La Roche\n2026-01-30\n2023-04-13\n204\nIncidence and Severity of Adverse Events\nNo Change\nNo changes yet\n\n\n\nNCT04457778\nFirst in Human Study of M6223\nEMD Serono Research & Development Institute, Inc.\n2023-12-08\n2020-07-10\n58\nPart 1A and 1B: Occurrence of Dose Limiting Toxicities (DLTs) During the DLT Observation Period (28 Days)\nNo Change\nNo changes yet\n\n\n\nNCT03772899\nFecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic)\nLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St.Â Josephâ€™s\n2025-03-28\n2019-03-27\n20\nTo evaluate the safety of combining Fecal Microbial Transplantation (FMT) using intestinal bacteria existing in the stool of healthy donors with immunotherapy in melanoma patients.\nNo Change\nNo changes yet\n\n\n\nNCT04374877\nStudy of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors\nCoherus Oncology, Inc.\n2025-11-10\n2020-04-22\n145\n[Part A] Dose Limiting Toxicity (DLT)\nNo Change\nNo changes yet\n\n\n\nNCT06346197\nCombination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas\nCentre Leon Berard\n2025-12-26\n2025-12-08\n132\nSurvival of patients\nNo Change\nNo changes yet\n\n\n\nNCT05780073\nSafety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment\nFundaciÃ³ Institut Germans Trias i Pujol\n2025-09-22\n2023-10-16\n60\nGrade 3 or 4 treatment-related adverse events or laboratory abnormalities during the study (based on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grading scale).\nNo Change\nNo changes yet\n\n\n\nNCT03667716\nCOM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.\nCompugen Ltd\n2025-01-17\n2018-09-06\n121\nIncidence of subjects with Adverse Events (AEs) as per CTCAE v4.03 and Dose-Limiting Toxicities (DLTs).\nNo Change\nNo changes yet\n\n\n\nNCT06784947\nTrial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer\nUniversity of Colorado, Denver\n2025-10-02\n2025-03-25\n13\nObjective Response Rate (ORR)\nNo Change\nNo changes yet\n\n\n\nNCT05014815\nOciperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer\nBeiGene\n2025-09-16\n2021-11-16\n272\nProgression-free Survival (PFS)\nNo Change\nNo changes yet\n\n\n\nNCT07307053\nRare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)\nCancer Institute and Hospital, Chinese Academy of Medical Sciences\n2025-12-29\n2026-01-01\n600\nObjective Response Rate (ORR)\nNo Change\nNo changes yet\n\n\n\nNCT04746924\nA Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer\nBeiGene\n2025-06-24\n2021-06-08\n662\nOverall Survival (OS)\nNo Change\nNo changes yet\n\n\n\nNCT07098338\nA Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)\nAstraZeneca\n2025-09-30\n2025-08-07\n278\nNumber of participants with adverse events (AE) and serious adverse events (SAE)\nNo Change\nNo changes yet\n\n\n\nNCT06532539\nCadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma\nShandong Cancer Hospital and Institute\n2024-08-01\n2024-06-13\n30\nProgression-Free Survival\nNo Change\nNo changes yet\n\n\n\nNCT06864598\nThe Application of Novel Identified CD8 Regulatory Precursors in Inducing Immune Tolerance After Allo-HSCT\nPeking University Peopleâ€™s Hospital\n2025-03-07\n2025-01-09\n100\nProportion of CD8 Trp subgroups\nNo Change\nNo changes yet\n\n\n\nNCT03661047\nOMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer\nMassachusetts General Hospital\n2021-11-17\n2019-11-30\n0\nThe change in the marine omega-3 polyunsaturated fatty acid (MO3PUFA) composition in colorectal tissues as a result of the AMR101 treatment for up to 30 days.\nNo Change\nNo changes yet\n\n\n\nNCT04866017\nA Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer\nBeiGene\n2024-10-31\n2021-06-17\n63\nProgression-Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)\nNo Change\nNo changes yet\n\n\n\nNCT05127824\nAutologous Dendritic Cell Vaccine in Kidney Cancer\nJodi Maranchie\n2025-05-04\n2023-07-06\n42\nProbability of immune response\nNo Change\nNo changes yet\n\n\n\nNCT04303169\nSubstudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)\nMerck Sharp & Dohme LLC\n2025-10-27\n2020-06-26\n146\nPercentage of participants who experience an adverse event (AE)\nNo Change\nNo changes yet\n\n\n\nNCT05329766\nA Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies\nArcus Biosciences, Inc.\n2026-01-29\n2022-06-10\n332\nNumber of Participants with Adverse Events (AEs)\nNo Change\nNo changes yet\n\n\n\nNCT04323202\nNeoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N\nCase Comprehensive Cancer Center\n2025-10-24\n2020-08-04\n13\nPathologic response as assessed by change in tumor volume (RECIST 1.1)\nNo Change\nNo changes yet\n\n\n\nNCT07221253\nA Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)\nAstraZeneca\n2026-01-08\n2025-12-04\n1100\nOverall Survival (OS) in the PDL1 â‰¥ 1% population\nNo Change\nNo changes yet\n\n\n\nNCT05676931\nStudy With Various Immunotherapy Treatments in Participants With Lung Cancer\nGilead Sciences\n2025-10-02\n2023-02-21\n400\nObjective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)\nNo Change\nNo changes yet\n\n\n\nNCT06790706\nIMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers\nHospices Civils de Lyon\n2025-10-06\n2025-10-01\n154\nProgression-free survival rate (cohort 1, 3 and 5)\nNo Change\nNo changes yet\n\n\n\nNCT04543617\nA Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy\nHoffmann-La Roche\n2026-01-20\n2020-09-28\n760\nArm A vs Arm C: Investigator-Assessed Progression-Free Survival (PFS)\nNo Change\nNo changes yet\n\n\n\nNCT04305041\nSubstudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)\nMerck Sharp & Dohme LLC\n2025-08-29\n2020-06-26\n100\nPercentage of participants who experience an adverse event (AE)\nNo Change\nNo changes yet\n\n\n\nNCT06996782\nA Platform Study in Non-Small Cell Lung Cancer (NSCLC)\nAstraZeneca\n2026-01-14\n2025-11-24\n152\nPart A and Part B: Number of participants with adverse events (AEs) and serious adverse events (SAEs)\nNo Change\nNo changes yet\n\n\n\nNCT05665595\nA Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)\nMerck Sharp & Dohme LLC\n2025-10-15\n2023-01-19\n1594\nRecurrence-Free Survival (RFS)\nNo Change\nNo changes yet\n\n\n\nNCT06868277\nA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer\nAstraZeneca\n2026-01-13\n2025-04-10\n830\nOverall Survival (OS)\nNo Change\nNo changes yet\n\n\n\nNCT06692738\nA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)\nAstraZeneca\n2026-01-21\n2024-11-18\n880\nOverall survival (OS)\nNo Change\nNo changes yet\n\n\n\nNCT04774484\nHigh-Intensity Interval Training and Regulatory T Cells\nFrancesc Marti\n2023-02-14\n2023-01\n0\nChange from baseline concentration of circulating Regulatory T cells (Tregs) in blood at 12 weeks post HIIT intervention\nNo Change\nNo changes yet\n\n\n\nNCT04256421\nA Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer\nHoffmann-La Roche\n2026-01-28\n2020-02-04\n490\nInvestigator-Assessed Progression Free Survival (PFS) in the Primary Analysis Set (PAS)\nNo Change\nNo changes yet\n\n\n\nNCT06989112\nDESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer\nAstraZeneca\n2026-01-15\n2025-03-27\n600\nProgression-free survival (PFS), as assessed by BICR\nNo Change\nNo changes yet\n\n\n\nNCT05816460\nThe Sleepio After Cancer Study\nUniversity College Dublin\n2023-05-23\n2023-05-22\n308\nMean continuous change in the intervention group compared to the control arm as measured by the Sleep Condition Indicator Score\nNo Change\nNo changes yet\n\n\n\nNCT06627647\nA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC\nAstraZeneca\n2025-12-22\n2024-11-27\n878\nOverall survival (OS)\nNo Change\nNo changes yet\n\n\n\nNCT04305054\nSubstudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)\nMerck Sharp & Dohme LLC\n2025-08-29\n2020-07-01\n315\nPercentage of participants who experience a dose-limiting toxicity (DLT): Safety lead-in phase\nNo Change\nNo changes yet\n\n\n\nNCT04294810\nA Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer\nHoffmann-La Roche\n2026-01-30\n2020-03-04\n620\nInvestigator-Assessed Progression-Free Survival (PFS) in the Primary Analysis Set\nNo Change\nNo changes yet\n\n\n\nNCT03198546\nGPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression\nSecond Affiliated Hospital of Guangzhou Medical University\n2024-06-25\n2017-07-01\n30\nNumber of Patients with Dose Limiting Toxicity\nNo Change\nNo changes yet\n\n\n\nNCT03198052\nGPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFÎ²/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers\nSecond Affiliated Hospital of Guangzhou Medical University\n2024-06-25\n2017-07-01\n30\nNumber of Patients with Dose Limiting Toxicity\nNo Change\nNo changes yet\n\n\n\nNCT04585815\nStudy of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)\nPfizer\n2026-01-09\n2020-11-10\n34\nPhase 1b of Sub-Study A: Percentage of Participants With Dose-Limiting Toxicities (DLT)\nNo Change\nNo changes yet\n\n\n\nNCT02443155\nA Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function\nNovo Nordisk A/S\n2021-04-09\n2015-11-10\n308\nArea Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 54 Relative to Baseline\nNo Change\nNo changes yet\n\n\n\n\nBack to Status Summary"
  },
  {
    "objectID": "index.html#monitoring-status",
    "href": "index.html#monitoring-status",
    "title": "Clinical Trial Watch",
    "section": "",
    "text": "This page monitors specific clinical trials and highlights any updates in their status or key fields.\nDownload Status Summary (CSV)\n\n\n\nTrial ID\nSponsor\nUpdate\nStatus\nConditions\nPhases\nStart\nEnd\nEnroll\nLast Updated\n\n\n\n\nNCT04818619\nAssiut University\nðŸŸ¢ No Change\nUNKNOWN\nChronic Myeloid Leukemia\nN/A\n2021-04\n2022-12\n65\nN/A\n\n\nNCT04150965\nMultiple Myeloma Research Consortium\nðŸŸ¢ No Change\nTERMINATED\nMultiple Myeloma, Relapsed Refractory Multiple Myeloma\nPHASE1, PHASE2\n2020-07-10\n2024-08-30\n14\nN/A\n\n\nNCT05607563\nBiotheus Inc.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumor\nPHASE1\n2022-11-21\n2023-12\n54\nN/A\n\n\nNCT05394168\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced/Metastatic Solid Tumors\nPHASE1\n2022-12-09\n2025-03-04\n12\nN/A\n\n\nNCT07171307\nInstituto de OftalmologÃ­a FundaciÃ³n Conde de Valenciana\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nConjunctivitis, Allergic\nN/A\n2026-01-01\n2026-09\n60\nN/A\n\n\nNCT04995523\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-Small-Cell Lung Carcinoma\nPHASE1, PHASE2\n2021-09-14\n2028-03-16\n210\nN/A\n\n\nNCT03119428\nOncoMed Pharmaceuticals, Inc.\nðŸŸ¢ No Change\nTERMINATED\nLocally Advanced Cancer, Metastatic Cancer\nPHASE1\n2017-05-02\n2019-05-15\n33\nN/A\n\n\nNCT04500678\nUniversity of Hawaii\nðŸŸ¢ No Change\nUNKNOWN\nHIV/AIDS\nPHASE2, PHASE3\n2019-02-01\n2022-12-31\n38\nN/A\n\n\nNCT05483400\nUniversity Medical Center Groningen\nðŸŸ¢ No Change\nRECRUITING\nHead and Neck Neoplasms, MSI-H Cancer, Melanoma\nPHASE2\n2023-10-18\n2027-09\n97\nN/A\n\n\nNCT05390528\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumors, Lymphoma, Metastatic Tumors\nPHASE1, PHASE2\n2022-06-20\n2024-12-30\n30\nN/A\n\n\nNCT06250036\nRoyal Marsden NHS Foundation Trust\nðŸŸ¢ No Change\nRECRUITING\nLocally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer\nPHASE2\n2025-02-20\n2031-09-01\n50\nN/A\n\n\nNCT05653284\nAkeso\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Malignant Tumors\nPHASE1\n2023-02-09\n2024-05-30\n19\nN/A\n\n\nNCT05102214\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nUNKNOWN\nLocally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer\nPHASE1, PHASE2\n2022-05-03\n2024-02\n150\nN/A\n\n\nNCT05023109\nShanghai Zhongshan Hospital\nðŸŸ¢ No Change\nUNKNOWN\nBiliary Tract Carcinoma\nPHASE2\n2021-02-01\n2024-12-01\n45\nN/A\n\n\nNCT05130177\nDiwakar Davar\nðŸŸ¢ No Change\nRECRUITING\nMelanoma\nPHASE2\n2022-03-16\n2031-01\n26\nN/A\n\n\nNCT04047862\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nLocally Advanced and Metastatic Solid Tumors\nPHASE1\n2019-08-15\n2024-08-07\n446\nN/A\n\n\nNCT05537051\nBiotheus Inc.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Solid Tumours\nPHASE1\n2023-10-30\n2025-12-31\n30\nN/A\n\n\nNCT05019677\nFudan University\nðŸŸ¢ No Change\nWITHDRAWN\nIntrahepatic Cholangiocarcinoma\nPHASE2\n2021-09-01\n2024-12-01\n0\nN/A\n\n\nNCT05061628\nShanghai Junshi Bioscience Co., Ltd.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumors\nPHASE1\n2021-04-21\n2024-09-30\n176\nN/A\n\n\nNCT04656535\nYale University\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nGlioblastoma\nEARLY_PHASE1\n2021-04-21\n2026-12-31\n46\nN/A\n\n\nNCT06773507\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\nðŸŸ¢ No Change\nRECRUITING\nAdvanced Esophageal Cancers, Advanced Non-small Cell Lung Cancer (NSCLC)\nPHASE1\n2025-05-12\n2027-06\n80\nN/A\n\n\nNCT06349980\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nRECRUITING\nCarcinoma, Hepatocellular\nPHASE2\n2024-08-05\n2027-02-10\n117\nN/A\n\n\nNCT05706207\nHuabo Biopharm Co., Ltd.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Solid Tumor\nPHASE1\n2021-12-21\n2023-09-30\n36\nN/A\n\n\nNCT05060432\niTeos Belgium SA\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma\nPHASE1, PHASE2\n2021-09-06\n2025-07\n153\nN/A\n\n\nNCT06713798\nGustave Roussy, Cancer Campus, Grand Paris\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nMetastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer\nPHASE2\n2025-07\n2030-01\n115\nN/A\n\n\nNCT05394337\nM.D.Â Anderson Cancer Center\nðŸŸ¢ No Change\nRECRUITING\nMetastatic Malignancy\nPHASE1, PHASE2\n2023-02-23\n2025-12-31\n10\nN/A\n\n\nNCT05253105\nShanghai Junshi Bioscience Co., Ltd.\nðŸŸ¢ No Change\nWITHDRAWN\nPreviously Treated, Advanced, Malignancies\nPHASE1\n2022-03-15\n2027-01\n0\nN/A\n\n\nNCT04270942\nProvention Bio, a Sanofi Company\nðŸŸ¢ No Change\nCOMPLETED\nDiabetes Mellitus, Type 1\nPHASE2\n2020-02-26\n2024-01-22\n6\nN/A\n\n\nNCT05294952\nAssiut University\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nPre-Eclampsia\nPHASE4\n2025-01-01\n2025-11-04\n82\nN/A\n\n\nNCT06754501\nM.D.Â Anderson Cancer Center\nðŸŸ¢ No Change\nRECRUITING\nCancer\nPHASE2\n2025-04-11\n2029-07-01\n35\nN/A\n\n\nNCT05757492\nCoherus Oncology, Inc.\nðŸŸ¢ No Change\nTERMINATED\nAdvanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma\nPHASE1\n2023-04-26\n2024-07-31\n22\nN/A\n\n\nNCT04952597\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nLimited Stage Small Cell Lung Cancer\nPHASE2\n2021-07-15\n2023-07-26\n126\nN/A\n\n\nNCT05805501\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nRenal Cell Carcinoma\nPHASE2\n2023-04-21\n2026-07-31\n199\nN/A\n\n\nNCT03447678\nFondazione IRCCS Istituto Nazionale dei Tumori, Milano\nðŸŸ¢ No Change\nUNKNOWN\nNon Small Cell Lung Cancer (NSCLC)\nPHASE2\n2018-05-23\n2022-05-31\n65\nN/A\n\n\nNCT04672369\nInnovent Biologics (Suzhou) Co.Â Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Lung Cancer\nPHASE1\n2021-06-06\n2023-06-01\n42\nN/A\n\n\nNCT04672356\nInnovent Biologics (Suzhou) Co.Â Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Lung Cancer\nPHASE1\n2021-01-25\n2023-06-01\n19\nN/A\n\n\nNCT05009069\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nRectal Neoplasms, Rectal Cancer\nPHASE2\n2022-03-18\n2026-11-06\n58\nN/A\n\n\nNCT04353830\nInnovent Biologics (Suzhou) Co.Â Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Malignancies\nPHASE1\n2020-05-22\n2022-05-11\n34\nN/A\n\n\nNCT07337447\nHospices Civils de Lyon\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nCarcinoma, Neuroendocrine\nPHASE2\n2026-04\n2030-04\n122\nN/A\n\n\nNCT04354246\nCompugen Ltd\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC\nPHASE1\n2020-03-31\n2025-12-30\n110\nN/A\n\n\nNCT04933227\nHoffmann-La Roche\nðŸŸ¢ No Change\nTERMINATED\nStomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma\nPHASE2\n2021-08-06\n2023-11-17\n29\nN/A\n\n\nNCT05414032\nUniversity Health Network, Toronto\nðŸŸ¢ No Change\nRECRUITING\nLocoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)\nPHASE2\n2023-07-12\n2026-07\n200\nN/A\n\n\nNCT06003621\nOmico\nðŸŸ¢ No Change\nRECRUITING\nSolid Tumor, Adult\nPHASE2\n2023-12-15\n2028-11-01\n96\nN/A\n\n\nNCT05568095\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Upper Gastrointestinal Tract Adenocarcinoma\nPHASE3\n2022-11-21\n2026-06\n1040\nN/A\n\n\nNCT06777628\nIRCCS Azienda Ospedaliero-Universitaria di Bologna\nðŸŸ¢ No Change\nRECRUITING\nLiver Cancer, Adult\nN/A\n2024-09-15\n2028-10-15\n100\nN/A\n\n\nNCT06773481\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\nðŸŸ¢ No Change\nRECRUITING\nGlioma, Glioma Tumor Recurrence, Glioma, Recurrent High Grade, Glioblastomas (GBM), Glioblastoma WHO Grade IV\nPHASE1\n2025-04-07\n2026-12\n40\nN/A\n\n\nNCT03708224\nAlain Algazi\nðŸŸ¢ No Change\nRECRUITING\nCancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer\nPHASE2\n2019-03-08\n2028-06-30\n55\nN/A\n\n\nNCT03652402\nAssistance Publique - HÃ´pitaux de Paris\nðŸŸ¢ No Change\nCOMPLETED\nKidney Transplant Rejection, Kidney Transplantation, Risk Stratification, Prognosis\nN/A\n2018-11-27\n2021-10-28\n558\nN/A\n\n\nNCT03486119\nYonsei University\nðŸŸ¢ No Change\nCOMPLETED\nNon -Small Cell Lung Cancer\nN/A\n2018-02-05\n2020-07-07\n60\nN/A\n\n\nNCT05120375\nBio-Thera Solutions\nðŸŸ¢ No Change\nTERMINATED\nSolid Tumor\nPHASE1\n2022-02-17\n2023-04-07\n5\nN/A\n\n\nNCT05327530\nEMD Serono Research & Development Institute, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nLocally Advanced or Metastatic Urothelial Carcinoma\nPHASE2\n2022-08-17\n2026-06-25\n256\nN/A\n\n\nNCT04570839\nCompugen Ltd\nðŸŸ¢ No Change\nCOMPLETED\nEndometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer\nPHASE1, PHASE2\n2020-08-31\n2024-05-15\n48\nN/A\n\n\nNCT05520294\nUniversity of Colorado, Denver\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nN/A\n2022-09-01\n2024-08-31\n90\nN/A\n\n\nNCT05417321\nShanghai Huaota Biopharmaceutical Co., Ltd.\nðŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumor, NSCLC\nPHASE1, PHASE2\n2022-08-25\n2025-08-01\n80\nN/A\n\n\nNCT06328036\nNational Cancer Institute (NCI)\nðŸŸ¢ No Change\nWITHDRAWN\nRecurrent Glioblastoma, IDH-Wildtype\nPHASE2\n2025-04-30\n2025-07-01\n0\nN/A\n\n\nNCT04465643\nSidney Kimmel Comprehensive Cancer Center at Johns Hopkins\nðŸŸ¢ No Change\nCOMPLETED\nNerve Sheath Tumors\nPHASE1\n2021-06-08\n2025-07-30\n13\nN/A\n\n\nNCT04262856\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer\nPHASE2\n2020-05-28\n2025-07-09\n151\nN/A\n\n\nNCT04736173\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer\nPHASE2\n2021-02-08\n2027-05\n169\nN/A\n\n\nNCT05126537\nSoutheast University, China\nðŸŸ¢ No Change\nUNKNOWN\n28 Day Mortality\nN/A\n2022-01-01\n2022-12-31\n100\nN/A\n\n\nNCT05289492\niTeos Therapeutics\nðŸŸ¢ No Change\nTERMINATED\nMultiple Myeloma\nPHASE1\n2022-05-01\n2023-11-29\n16\nN/A\n\n\nNCT07115043\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nMelanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma\nPHASE1, PHASE2\n2025-07-29\n2029-10-02\n60\nN/A\n\n\nNCT05743504\nNational Taiwan University Hospital\nðŸŸ¢ No Change\nUNKNOWN\nLocally Advanced Esophageal Squamous Cell Carcinoma\nPHASE1, PHASE2\n2023-09-18\n2025-11-30\n32\nN/A\n\n\nNCT05073484\nBio-Thera Solutions\nðŸŸ¢ No Change\nTERMINATED\nAdvanced Solid Tumor\nPHASE1\n2021-10-29\n2023-03-30\n13\nN/A\n\n\nNCT07376512\nCentre Georges Francois Leclerc\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nNon-Small Cell Lung Cancer, Melanoma (Skin Cancer)\nN/A\n2026-03-01\n2030-03-01\n378\nN/A\n\n\nNCT05904886\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nHepatocellular Carcinoma\nPHASE3\n2023-09-14\n2026-09-01\n687\nN/A\n\n\nNCT03739710\nGlaxoSmithKline\nðŸŸ¢ No Change\nCOMPLETED\nNeoplasms\nPHASE2\n2019-01-24\n2024-05-02\n175\nN/A\n\n\nNCT04791839\nWashington University School of Medicine\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer\nPHASE2\n2021-08-04\n2030-06-30\n30\nN/A\n\n\nNCT05020912\nCase Comprehensive Cancer Center\nðŸŸ¢ No Change\nRECRUITING\nBasal Cell Carcinoma\nPHASE2\n2021-12-13\n2027-12\n28\nN/A\n\n\nNCT06334406\nCentre Hospitalier Universitaire de Besancon\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nBladder Cancer\nN/A\n2024-04-02\n2026-04-02\n33\nN/A\n\n\nNCT07343310\nKine Sciences Co., Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nCIDP - Chronic Inflammatory Demyelinating Polyneuropathy\nPHASE1\n2024-08-27\n2025-04-14\n9\nN/A\n\n\nNCT03342417\nExcellaBio LLC\nðŸŸ¢ No Change\nTERMINATED\nBreast Cancer Female, Ovarian Cancer, Gastric Cancer\nPHASE2\n2018-02-14\n2019-05-29\n5\nN/A\n\n\nNCT04682665\nUniversity of Leeds\nðŸŸ¢ No Change\nCOMPLETED\nColon Cancer Liver Metastasis\nN/A\n2021-09-16\n2024-07-31\n81\nN/A\n\n\nNCT05123482\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nBreast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer\nPHASE1, PHASE2\n2021-10-18\n2027-09-29\n460\nN/A\n\n\nNCT07161414\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumors\nPHASE1\n2025-11-25\n2029-07-24\n40\nN/A\n\n\nNCT07015164\nAssistance Publique - HÃ´pitaux de Paris\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nHIV\nN/A\n2025-06-10\n2026-09-11\n80\nN/A\n\n\nNCT05702229\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nGastric Cancer\nPHASE2\n2023-01-16\n2027-09-28\n240\nN/A\n\n\nNCT07213882\nAssistance Publique - HÃ´pitaux de Paris\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nCutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome\nEARLY_PHASE1\n2026-01-01\n2028-08-01\n30\nN/A\n\n\nNCT03628677\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nSolid Tumor, Unspecified, Adult\nPHASE1\n2018-09-12\n2025-01-23\n75\nN/A\n\n\nNCT06897436\nMedical University of Lublin\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nEndometriosis\nN/A\n2025-05-01\n2029-12-31\n60\nN/A\n\n\nNCT05633927\nHospitales Universitarios Virgen del RocÃ­o\nðŸŸ¢ No Change\nCOMPLETED\nSARS-CoV-2 RNA Vaccines, HIV Infection\nN/A\n2021-04-01\n2022-12-01\n48\nN/A\n\n\nNCT04836507\nCurocell Inc.\nðŸŸ¢ No Change\nRECRUITING\nRelapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal Large B-Cell Lymphoma (PMBCL), High-grade B-cell Lymphoma, Transformed Follicular Lymphoma (TFL)\nPHASE1, PHASE2\n2021-03-02\n2028-02\n91\nN/A\n\n\nNCT05775159\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nHepatocellular Carcinoma, Biliary Tract Cancer\nPHASE2\n2023-04-24\n2027-10-28\n294\nN/A\n\n\nNCT06338657\nUniversity of Southern California\nðŸŸ¢ No Change\nTERMINATED\nHead and Neck Squamous Cell Carcinoma\nPHASE1\n2024-04-01\n2025-09-09\n1\nN/A\n\n\nNCT06860815\nCity of Hope Medical Center\nðŸŸ¢ No Change\nRECRUITING\nAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver\nPHASE2\n2026-04-01\n2027-01-30\n11\nN/A\n\n\nNCT04624828\nIstituto Clinico Humanitas\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nOligorecurrent and Oligoprogressive Prostate Cancer Patients\nNA\n2020-10-19\n2026-07\n40\nN/A\n\n\nNCT05574335\nNational Institute of Allergy and Infectious Diseases (NIAID)\nðŸŸ¢ No Change\nTERMINATED\nType 1 Diabetes Mellitus\nPHASE1, PHASE2\n2023-04-26\n2025-10-20\n8\nN/A\n\n\nNCT06302556\nFondazione IRCCS Caâ€™ Granda, Ospedale Maggiore Policlinico\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nLung Transplant Rejection\nN/A\n2024-04\n2026-02\n280\nN/A\n\n\nNCT04761198\nMereo BioPharma\nðŸŸ¢ No Change\nCOMPLETED\nSolid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor\nPHASE1, PHASE2\n2021-03-23\n2023-10-30\n76\nN/A\n\n\nNCT04693234\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nCervical Cancer\nPHASE2\n2021-02-15\n2023-08-31\n178\nN/A\n\n\nNCT03563716\nGenentech, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nNon-small Cell Lung Cancer\nPHASE2\n2018-08-10\n2025-11-24\n135\nN/A\n\n\nNCT07324642\nKine Sciences Co., Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nHealthy Volunteers\nPHASE1\n2025-05-26\n2025-08-25\n24\nN/A\n\n\nNCT05809895\nNovartis Pharmaceuticals\nðŸŸ¢ No Change\nWITHDRAWN\nTriple Negative Breast Cancer\nPHASE2\n2023-09-15\n2029-07-18\n0\nN/A\n\n\nNCT04732494\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nEsophageal Squamous Cell Carcinoma\nPHASE2\n2021-03-31\n2023-12-26\n125\nN/A\n\n\nNCT05645692\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nUrothelial Cancer\nPHASE2\n2023-04-13\n2026-12-31\n204\nN/A\n\n\nNCT04457778\nEMD Serono Research & Development Institute, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nMetastatic Solid Tumors\nPHASE1\n2020-07-10\n2023-06-23\n58\nN/A\n\n\nNCT03772899\nLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St.Â Josephâ€™s\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nPHASE1\n2019-03-27\n2026-08\n20\nN/A\n\n\nNCT04374877\nCoherus Oncology, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer\nPHASE1\n2020-04-22\n2025-06-05\n145\nN/A\n\n\nNCT06346197\nCentre Leon Berard\nðŸŸ¢ No Change\nRECRUITING\nGastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer\nPHASE3\n2025-12-08\n2028-05-15\n132\nN/A\n\n\nNCT05780073\nFundaciÃ³ Institut Germans Trias i Pujol\nðŸŸ¢ No Change\nCOMPLETED\nHIV Infection Primary\nPHASE2\n2023-10-16\n2025-04-01\n60\nN/A\n\n\nNCT03667716\nCompugen Ltd\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer\nPHASE1\n2018-09-06\n2024-01-30\n121\nN/A\n\n\nNCT06784947\nUniversity of Colorado, Denver\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMicrosatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV\nPHASE2\n2025-03-25\n2028-05\n13\nN/A\n\n\nNCT05014815\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nLocally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV\nPHASE2\n2021-11-16\n2024-09-04\n272\nN/A\n\n\nNCT07307053\nCancer Institute and Hospital, Chinese Academy of Medical Sciences\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nRare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors\nPHASE1, PHASE2\n2026-01-01\n2031-01-31\n600\nN/A\n\n\nNCT04746924\nBeiGene\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon-small Cell Lung Cancer, NSCLC\nPHASE3\n2021-06-08\n2026-03-31\n662\nN/A\n\n\nNCT07098338\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-Small Cell Lung Cancer\nPHASE2\n2025-08-07\n2029-04-06\n278\nN/A\n\n\nNCT06532539\nShandong Cancer Hospital and Institute\nðŸŸ¢ No Change\nRECRUITING\nEndometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis\nPHASE2\n2024-06-13\n2026-05\n30\nN/A\n\n\nNCT06864598\nPeking University Peopleâ€™s Hospital\nðŸŸ¢ No Change\nENROLLING_BY_INVITATION\nGraft-versus-host Disease (GVHD)\nN/A\n2025-01-09\n2026-10-31\n100\nN/A\n\n\nNCT03661047\nMassachusetts General Hospital\nðŸŸ¢ No Change\nWITHDRAWN\nColon Cancer\nPHASE2\n2019-11-30\n2021-11-30\n0\nN/A\n\n\nNCT04866017\nBeiGene\nðŸŸ¢ No Change\nTERMINATED\nNon Small Cell Lung Cancer\nPHASE3\n2021-06-17\n2023-10-17\n63\nN/A\n\n\nNCT05127824\nJodi Maranchie\nðŸŸ¢ No Change\nRECRUITING\nCarcinoma, Renal Cell\nPHASE2\n2023-07-06\n2026-12\n42\nN/A\n\n\nNCT04303169\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE1, PHASE2\n2020-06-26\n2025-09-24\n146\nN/A\n\n\nNCT05329766\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nGastrointestinal Tract Malignancies\nPHASE2\n2022-06-10\n2027-06\n332\nN/A\n\n\nNCT04323202\nCase Comprehensive Cancer Center\nðŸŸ¢ No Change\nCOMPLETED\nBasal Cell Carcinoma of the Head and Neck\nPHASE1\n2020-08-04\n2025-06-25\n13\nN/A\n\n\nNCT07221253\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nBiliary Tract Cancer\nPHASE3\n2025-12-04\n2029-07-04\n1100\nN/A\n\n\nNCT05676931\nGilead Sciences\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Non-Small Cell Lung Cancer\nPHASE2\n2023-02-21\n2027-12\n400\nN/A\n\n\nNCT06790706\nHospices Civils de Lyon\nðŸŸ¢ No Change\nRECRUITING\nPeritoneal Mesothelioma, Gestational Trophoblastic Tumor, Thymoma and Thymic Carcinoma, Anaplastic Thyroid Carcinomas, Gastroenteropancreatic Neuroendocrine Tumor, Carcinoid Tumor\nPHASE2\n2025-10-01\n2031-06\n154\nN/A\n\n\nNCT04543617\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nEsophageal Squamous Cell Carcinoma\nPHASE3\n2020-09-28\n2027-03-31\n760\nN/A\n\n\nNCT04305041\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE1, PHASE2\n2020-06-26\n2025-08-25\n100\nN/A\n\n\nNCT06996782\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nAdvanced or Metastatic Non-small Cell Lung Cancer\nPHASE1, PHASE2\n2025-11-24\n2029-02-23\n152\nN/A\n\n\nNCT05665595\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE3\n2023-01-19\n2025-09-26\n1594\nN/A\n\n\nNCT06868277\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nCarcinoma, Non-Small Cell Lung\nPHASE3\n2025-04-10\n2030-12-02\n830\nN/A\n\n\nNCT06692738\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-small Cell Lung Cancer\nPHASE3\n2024-11-18\n2029-10-08\n880\nN/A\n\n\nNCT04774484\nFrancesc Marti\nðŸŸ¢ No Change\nWITHDRAWN\nEnd Stage Renal Disease\nNA\n2023-01\n2026-06-30\n0\nN/A\n\n\nNCT04256421\nHoffmann-La Roche\nðŸŸ¢ No Change\nCOMPLETED\nSmall Cell Lung Cancer\nPHASE3\n2020-02-04\n2025-07-31\n490\nN/A\n\n\nNCT06989112\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nEndometrial Cancer\nPHASE3\n2025-03-27\n2031-02-19\n600\nN/A\n\n\nNCT05816460\nUniversity College Dublin\nðŸŸ¢ No Change\nUNKNOWN\nInsomnia, Cancer\nNA\n2023-05-22\n2024-06-10\n308\nN/A\n\n\nNCT06627647\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-squamous Non-small Cell Lung Cancer\nPHASE3\n2024-11-27\n2030-03-25\n878\nN/A\n\n\nNCT04305054\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nPHASE1, PHASE2\n2020-07-01\n2026-04-20\n315\nN/A\n\n\nNCT04294810\nHoffmann-La Roche\nðŸŸ¢ No Change\nCOMPLETED\nNon-Small Cell Lung Cancer\nPHASE3\n2020-03-04\n2025-12-30\n620\nN/A\n\n\nNCT03198546\nSecond Affiliated Hospital of Guangzhou Medical University\nðŸŸ¢ No Change\nRECRUITING\nHepatocellular Carcinoma, Immunotherapy, CAR, GPC3 Gene Inactivation, T Cell, Squamous Cell Lung Cancer\nPHASE1\n2017-07-01\n2036-08-01\n30\nN/A\n\n\nNCT03198052\nSecond Affiliated Hospital of Guangzhou Medical University\nðŸŸ¢ No Change\nRECRUITING\nLung Cancer, Cancer, Immunotherapy, CAR-T Cell\nPHASE1\n2017-07-01\n2036-08-01\n30\nN/A\n\n\nNCT04585815\nPfizer\nðŸŸ¢ No Change\nTERMINATED\nCarcinoma, Non-Small-Cell Lung\nPHASE1, PHASE2\n2020-11-10\n2024-10-29\n34\nN/A\n\n\nNCT02443155\nNovo Nordisk A/S\nðŸŸ¢ No Change\nCOMPLETED\nDiabetes, Diabetes Mellitus, Type 1\nPHASE2\n2015-11-10\n2019-02-27\n308\nN/A\n\n\n\nView Full Change History"
  },
  {
    "objectID": "full_data.html#consolidated-raw-snapshots",
    "href": "full_data.html#consolidated-raw-snapshots",
    "title": "Full Snapshot Data",
    "section": "",
    "text": "This page displays the consolidated raw data from all monitored trial snapshots. This includes all fields from ClinicalTrials.gov in a flattened format.\nDownload Full Snapshots (CSV)\n\n\n\nBack to Status Summary"
  }
]